CAGR For OTC Switch Forecast At 5%, But Without Statins, Asthma Treatments
This article was originally published in The Tan Sheet
OTC switch product sales are estimated to grow at a compounded annual growth rate of 5% by 2019, with opportunities likely emerging in bladder control for women and sleep aids, according to Kline Market Research. But asthma drugs and statins are not likely to debut OTC soon, notes analyst Laura Mahecha.
Register for our free email digests: